查詢結果分析
相關文獻
- Effects of Zafirlukast on Patients with Severe Steroid-dependent Asthma: A Prospective Study
- Airway Hyperreactivity Modulated by Immunotherapy with Denatured Ovalbumin in Ovalbumin-Sensitized Guinea Pigs
- 過敏性氣喘
- 麻杏甘石湯對塵蟍誘發氣喘天竺鼠之影響
- 各年齡層氣喘病人食物過敏率與過敏程度之研究
- The Anti-Inflammatory Effect of a Long-Acting Theophylline (Unidur) in Patients with Bronchial Asthma
- 腎氣丸對塵蟍激發喘天竺鼠呼吸道發炎與免疫之影響
- 如何改善老年人氣喘病的療效
- 小兒氣喘處置之最新發展
- 氣喘的另類治療
頁籤選單縮合
題 名 | Effects of Zafirlukast on Patients with Severe Steroid-dependent Asthma: A Prospective Study=Zafirlukast在重度類固醇依賴型氣喘病人身上的效果評估 |
---|---|
作 者 | 王德源; 楊泮池; 夏德椿; 杭良文; 邱國樑; 余養豪; 陳淑真; | 書刊名 | 中臺灣醫學科學雜誌 |
卷 期 | 6:3 2001.09[民90.09] |
頁 次 | 頁139-146 |
分類號 | 418.263 |
關鍵詞 | 氣喘; 白三烯介質拮抗劑; Asthma; Leukotriene receptor antagonist; |
語 文 | 英文(English) |
中文摘要 | 背景:慢性重度氣喘病人需要長期口服類固醇以控制氣喘會導致許多後遺症。有許多藥物被嚐試用來替代口服類固醇。Zafirlukast,一種白三烯介質拮抗劑,已被證明在輕度與中度氣喘病人可改善其肺功能,本研究主要是瞭解 Zafirlukast 在重度氣喘病人之療效。方法:本研究隨意雙盲試驗,利用兩星期篩選期做六星期之治療期。病患分成兩組,治療組每天給予Zafirlukast 20 mg一天兩次,對照組給予安慰劑。結果:在治療六星期後,發現治療組在第一秒用力呼(吐)氣肺容積(forced expiratory volume in firstsecond,FEV1)有15%的改善,其每週平均尖峰流速有22%改善,而且也可逐量降低口服類固醇的劑量。但在對照組卻未有上述改善。結論:Zafirlukast可明顯改善在慢性重度氣喘病人的口服類固醇劑量,雖然其改善氣喘的效果個人差異性很大,但在重度氣喘的病人仍有一定的療效。 |
英文摘要 | Background: Many patients with chronic, severe asthma are steroid dependent, requiring daily oral corticosteroids which may cause intolerable side effects. Various medications have been tried as steroid-sparing agents in patients who suffer from the side effects of long-term oral corticosteroids. Zafirlukast, a leukotriene receptor antagonist, has been shown to improve forced expiratory volume (FEV��)and peak expiratory flow rates (PEFR)in patients with mild to moderate asthma. This study was conducted in order to investigate the effects of Zafirlukast on patients with severe, steroid-dependent asthma. Methods:This randomized, double-blinded, placebo-controlled study consists of three periods:a 10-wk baseline period, a 2-wk screening period and a 6-wk treatment period. During the treatment period, the patients were randomly divided into two groups:one received Zafirlukast 20 mg orally twice a day (Zafirlukast group) and the other group received placebo (control group). The drugs for their asthma were not changed and only the oral corticosteroid was adjusted according to the clinical condition. Results:In comparison with the control group, the FEV1 in patients in the treatment group increased by 15% of the predicted value despite a reduction of oral prednisolone after 6 weeks (P<0.001). Likewise, the mean weekly PEFR increased by 22% of the predicted value. By contrast, these variables remained under the baseline value in the placebo group. The time trends analysis of the mean weekly prednisolone doses in the Zafirlukast group revealed a statistically significant difference, indicating that Zafirlukast was more effective than the placebo in reducing the requirement for systemic oral prednisolone. Conclusions:Zafirlukast can improve pulmonary function and reduce the needed dosage of oral steroids in patients with chronic severe asthma. Although the degree of bronchodilation was highly individualized, our data showed that Zafirlukast could be considered an effective drug for severe steroid-dependent asthma by reducing the daily dose of oral prednisolone. |
本系統中英文摘要資訊取自各篇刊載內容。